Brief: Compugen Expands Com701 Intellectual Property Portfolio With New U.S. Patent
18/01/2022 14:51
Jan 18 (Reuters) - Compugen Ltd CGEN.TA :
* COMPUGEN EXPANDS COM701 INTELLECTUAL PROPERTY PORTFOLIO
WITH NEW
U.S. PATENT COVERING TRIPLE COMBINATION USE WITH ANTI-PD-1 AND
ANTI-TIGIT ANTIBODIES
Source text for Eikon: ID:nPnbg3HYXa
Further company coverage: CGEN.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Compugen
See all newsIsrael's Compugen Q2 revenue more than doubles, net loss narrows
Brief: Compugen Announces The Appointment Of Michele Holcomb, Ph.D., To Its Board Of Directors
Brief: Compugen Monetizes Portion Of Rilvegostomig Future Royalties To Astrazeneca For Up To $90 Million
Brief: Compugen Announces First Patient Dosed In Com701 Global Platform Trial In Platinum Sensitive Ovarian Cancer
Brief: Compugen Announces Leadership Transitions Effective September 2025